Components of tumor stroma-immune microenvironment and their interactions in intrahepatic cholangiocarcinoma

Qiulu ZHANG; Zhuo LI; Congrong LIU; Limei GUO

doi:10.12449/JCH250331

Volume 41 Issue 3

Mar. 2025

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(3): 594-600

PDF( 1621 KB)

Components of tumor stroma-immune microenvironment and their interactions in intrahepatic cholangiocarcinoma

DOI: 10.12449/JCH250331

1.
Department of Pathology，Peking University Third Hospital/Department of Pathology，Peking University Health Science Center，Beijing 100191，China
2.
National Cancer Center/National Clinical Research Center for Cancer/Department of Pathology，Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing 100021，China

More Information

Corresponding author: GUO Limei， guolimei@bjmu.edu.cn （ORCID： 0000-0003-0430-2914）
Received Date: 2024-06-25
Accepted Date: 2024-08-15
Published Date: 2025-03-25

Abstract

Abstract

Intrahepatic cholangiocarcinoma （ICC） is a highly malignant liver tumor， and due to the absence of symptoms in its early stage and the lack of effective treatment measures， patients tend to have an extremely low 5-year survival rate. The tumor stroma-immune microenvironment （TSIME） is a complex ecosystem that changes dynamically during tumorigenesis and evolution and consists of a variety of cellular and non-cellular components， and it plays an important role in the development， proliferation， invasion， and progression of ICC and determines the heterogeneity and malignancy of ICC to a certain degree. This article reviews the cellular components （such as T cells， B cells， natural killer cells， dendritic cells， neutrophils， macrophages， myeloid-derived suppressor cells） and non-cellular components （such as chemokines and cytokines） within the ICC TSIME， as well as the complex mechanisms of interaction between these components， and it also reviews the spatial interactions between immune cells and tumor cells， in order to provide potential research directions for ICC immunotherapy and new ideas for the effective and precise treatment of ICC in the future.
- Cholangiocarcinoma,
- Tumor Microenvironment,
- Lymphocytes

FullText(HTML)

References(49)

References

[1]	BRINDLEY PJ, BACHINI M, ILYAS SI, et al. Cholangiocarcinoma[J]. Nat Rev Dis Primers, 2021, 7( 1): 65. DOI: 10.1038/s41572-021-00300-2.
[2]	RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77( 6): 1598- 1606. DOI: 10.1016/j.jhep.2022.08.021.
[3]	Expert Committee of Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma( 2022 version). Expert consensus on pathological diagnosis of intrahepatic cholangiocarcinoma(2022 version)[J]. Chin J Pathol, 2022, 51( 9): 819- 827. DOI: 10.3760/cma.j.cn112151-20220517-00423. 《肝内胆管癌病理诊断专家共识(2022版)》编写专家委员会. 肝内胆管癌病理诊断专家共识(2022版)[J]. 中华病理学杂志, 2022, 51( 9): 819- 827. DOI: 10.3760/cma.j.cn112151-20220517-00423.
[4]	WANG GY, HE CH. Progress in liver transplantation for intrahepatic cholangiocarcinoma[J]. Organ Transplantation, 2023, 14( 6): 789- 796. DOI: 10.3969/j.issn.1674-7445.2023144. 汪国营, 何才华. 肝移植治疗肝内胆管癌的研究进展[J]. 器官移植, 2023, 14( 6): 789- 796. DOI: 10.3969/j.issn.1674-7445.2023144.
[5]	MORIS D, PALTA M, KIM C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians[J]. CA Cancer J Clin, 2023, 73( 2): 198- 222. DOI: 10.3322/caac.21759.
[6]	KOSHIOL J, YU BB, KABADI SM, et al. Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015[J]. BMC Cancer, 2022, 22( 1): 1178. DOI: 10.1186/s12885-022-10286-z.
[7]	JIN MZ, JIN WL. The updated landscape of tumor microenvironment and drug repurposing[J]. Signal Transduct Target Ther, 2020, 5( 1): 166. DOI: 10.1038/s41392-020-00280-x.
[8]	FABRIS L, PERUGORRIA MJ, MERTENS J, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma[J]. Liver Int, 2019, 39( Suppl 1): 63- 78. DOI: 10.1111/liv.14098.
[9]	GENTILINI A, PASTORE M, MARRA F, et al. The role of stroma in cholangiocarcinoma: The intriguing interplay between fibroblastic component, immune cell subsets and tumor epithelium[J]. Int J Mol Sci, 2018, 19( 10): 2885. DOI: 10.3390/ijms19102885.
[10]	LOEUILLARD E, CONBOY CB, GORES GJ, et al. Immunobiology of cholangiocarcinoma[J]. JHEP Rep, 2019, 1( 4): 297- 311. DOI: 10.1016/j.jhepr.2019.06.003.
[11]	LIN J, DAI YT, SANG C, et al. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities[J]. J Immunother Cancer, 2022, 10( 7): e004892. DOI: 10.1136/jitc-2022-004892.
[12]	RUFFOLO LI, JACKSON KM, KUHLERS PC, et al. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity[J]. Gut, 2022, 71( 7): 1386- 1398. DOI: 10.1136/gutjnl-2021-324109.
[13]	LIU D, HEIJ LR, CZIGANY Z, et al. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma[J]. J Exp Clin Cancer Res, 2022, 41( 1): 127. DOI: 10.1186/s13046-022-02340-2.
[14]	XIA T, LI KY, NIU N, et al. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses[J]. J Hematol Oncol, 2022, 15( 1): 37. DOI: 10.1186/s13045-022-01253-z.
[15]	FABRIS L, SATO K, ALPINI G, et al. The tumor microenvironment in cholangiocarcinoma progression[J]. Hepatology, 2021, 73( Suppl 1): 75- 85. DOI: 10.1002/hep.31410.
[16]	CHEN Z, YU MC, YAN JL, et al. PNOC expressed by B cells in cholangiocarcinoma was survival related and LAIR2 could be a T cell exhaustion biomarker in tumor microenvironment: Characterization of immune microenvironment combining single-cell and bulk sequencing technology[J]. Front Immunol, 2021, 12: 647209. DOI: 10.3389/fimmu.2021.647209.
[17]	THEPMALEE C, PANYA A, JUNKING M, et al. Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells[J]. Hum Vaccin Immunother, 2018, 14( 6): 1423- 1431. DOI: 10.1080/21645515.2018.1431598.
[18]	SAUTÈS-FRIDMAN C, PETITPREZ F, CALDERARO J, et al. Tertiary lymphoid structures in the era of cancer immunotherapy[J]. Nat Rev Cancer, 2019, 19( 6): 307- 325. DOI: 10.1038/s41568-019-0144-6.
[19]	DOI N, INO Y, FUSE M, et al. Correlation of vein-rich tumor microenvironment of intrahepatic cholangiocarcinoma with tertiary lymphoid structures and patient outcome[J]. Mod Pathol, 2024, 37( 2): 100401. DOI: 10.1016/j.modpat.2023.100401.
[20]	DING GY, MA JQ, YUN JP, et al. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma[J]. J Hepatol, 2022, 76( 3): 608- 618. DOI: 10.1016/j.jhep.2021.10.030.
[21]	SHI HN, LI ZS, ZHU MC. Circulating immune cells predict prognosis and clinical response to chemotherapy in cholangiocarcinoma[J]. Curr Med Chem, 2024. DOI: 10.2174/0109298673296618240424095548.[ Online ahead of print]
[22]	OLIVIERO B, VARCHETTA S, MELE D, et al. MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma[J]. Oncoimmunology, 2022, 11( 1): 2035919. DOI: 10.1080/2162402X.2022.2035919.
[23]	VITA F, OLAIZOLA I, AMATO F, et al. Heterogeneity of cholangiocarcinoma immune biology[J]. Cells, 2023, 12( 6): 846. DOI: 10.3390/cells12060846.
[24]	DIGGS LP, RUF B, MA C, et al. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma[J]. J Hepatol, 2021, 74( 5): 1145- 1154. DOI: 10.1016/j.jhep.2020.11.037.
[25]	CAZZETTA V, FRANZESE S, CARENZA C, et al. Natural killer-dendritic cell interactions in liver cancer: Implications for immunotherapy[J]. Cancers(Basel), 2021, 13( 9): 2184. DOI: 10.3390/cancers13092184.
[26]	SUNG E, KO M, WON JY, et al. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation[J]. Mol Ther, 2022, 30( 8): 2800- 2816. DOI: 10.1016/j.ymthe.2022.05.003.
[27]	WANG WM, GAO Y, XU JJ, et al. A NRF2 regulated and the immunosuppressive microenvironment reversed nanoplatform for cholangiocarcinoma photodynamic-gas therapy[J]. Adv Sci(Weinh), 2024, 11( 14): e2307143. DOI: 10.1002/advs.202307143.
[28]	XUE RD, ZHANG QM, CAO Q, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity[J]. Nature, 2022, 612( 7938): 141- 147. DOI: 10.1038/s41586-022-05400-x.
[29]	ZHOU ZJ, WANG PC, SUN RQ, et al. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3[J]. J Immunother Cancer, 2021, 9( 3): e001946. DOI: 10.1136/jitc-2020-001946.
[30]	WATANABE A, HARIMOTO N, ARAKI K, et al. Absolute neutrophil count predicts postoperative prognosis in mass-forming intrahepatic cholangiocarcinoma[J]. Anticancer Res, 2019, 39( 2): 941- 947. DOI: 10.21873/anticanres.13197.
[31]	ZHOU MH, WANG CQ, LU SN, et al. Tumor-associated macrophages in cholangiocarcinoma: Complex interplay and potential therapeutic target[J]. EBioMedicine, 2021, 67: 103375. DOI: 10.1016/j.ebiom.2021.103375.
[32]	ZENG JH, LIU ZK, SUN SW, et al. Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells[J]. Oncol Lett, 2018, 15( 6): 8681- 8686. DOI: 10.3892/ol.2018.8372.
[33]	SUN DL, LUO TC, DONG PP, et al. M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma[J]. J Cell Biochem, 2020, 121( 4): 2828- 2838. DOI: 10.1002/jcb.29514.
[34]	CHENG K, CAI N, ZHU JH, et al. Tumor-associated macrophages in liver cancer: From mechanisms to therapy[J]. Cancer Commun(Lond), 2022, 42( 11): 1112- 1140. DOI: 10.1002/cac2.12345.
[35]	RAGGI C, CORRENTI M, SICA A, et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages[J]. J Hepatol, 2017, 66( 1): 102- 115. DOI: 10.1016/j.jhep.2016.08.012.
[36]	QUARANTA V, BALLARÒ C, GIANNELLI G. Macrophages orchestrate the liver tumor microenvironment[J]. Cancers(Basel), 2024, 16( 9): 1772. DOI: 10.3390/cancers16091772.
[37]	LUO CB, XIN HY, ZHOU ZJ, et al. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression[J]. Hepatology, 2022, 76( 4): 982- 999. DOI: 10.1002/hep.32387.
[38]	TOMLINSON JL, VALLE JW, ILYAS SI. Immunobiology of cholangiocarcinoma[J]. J Hepatol, 2023, 79( 3): 867- 875. DOI: 10.1016/j.jhep.2023.05.010.
[39]	LIN YL, CAI Q, CHEN Y, et al. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase[J]. Hepatology, 2022, 75( 1): 28- 42. DOI: 10.1002/hep.32099.
[40]	AFFO S, YU LX, SCHWABE RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer[J]. Annu Rev Pathol, 2017, 12: 153- 186. DOI: 10.1146/annurev-pathol-052016-100322.
[41]	ZHENG Y, ZHOU C, YU XX, et al. Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-Catenin[J]. Cell Death Dis, 2018, 9( 2): 179. DOI: 10.1038/s41419-017-0226-x.
[42]	GRACIA-SANCHO J, CAPARRÓS E, FERNÁNDEZ-IGLESIAS A, et al. Role of liver sinusoidal endothelial cells in liver diseases[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 6): 411- 431. DOI: 10.1038/s41575-020-00411-3.
[43]	COGLIATI B, YASHASWINI CN, WANG S, et al. Friend or foe? The elusive role of hepatic stellate cells in liver cancer[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 10): 647- 661. DOI: 10.1038/s41575-023-00821-z.
[44]	YUAN H, LIN ZL, LIU YJ, et al. Intrahepatic cholangiocarcinoma induced M2-polarized tumor-associated macrophages facilitate tumor growth and invasiveness[J]. Cancer Cell Int, 2020, 20( 1): 586. DOI: 10.1186/s12935-020-01687-w.
[45]	ZHU CB, MA JQ, ZHU K, et al. Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma[J]. JHEP Rep, 2023, 5( 8): 100762. DOI: 10.1016/j.jhepr.2023.100762.
[46]	LIN YP, PENG LH, DONG LQ, et al. Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma[J]. Cancer Discov, 2022, 12( 10): 2350- 2371. DOI: 10.1158/2159-8290.CD-21-1640.
[47]	HONG JH, YONG CH, HENG H, et al. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies[J]. Gut, 2024, 73( 6): 966- 984. DOI: 10.1136/gutjnl-2023-330483.
[48]	CHEN JL, TANG Y, QIN DL, et al. ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway[J]. J Transl Med, 2023, 21( 1): 923. DOI: 10.1186/s12967-023-04804-1.
[49]	XU LX, ZHANG Y, LIN ZL, et al. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma[J]. J Hepatol, 2024, 81( 2): 265- 277. DOI: 10.1016/j.jhep.2024.03.016.

Relative Articles

[1]	Xiaoli LIU, Qinwen TAN, Jian XU, Huanling CHEN, Jie YU, Lu LU, Mingkan DAI, Jingjing HUANG, Hongna HUANG, Dewen MAO. Effect of amino acid metabolic reprogramming on immune microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2531-2537. doi: 10.12449/JCH241226
[2]	Jun LIU, Ling WANG, Yuhuan JIANG, Jingzhi WANG, Huiming LI. Establishment of a risk model based on immunogenic cell death-related genes and its value in predicting the prognosis and tumor microenvironment characteristics of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2473-2483. doi: 10.12449/JCH241218
[3]	Xiaohua ZHANG, Ying FENG, Xianbo WANG. Role of the Hedgehog signaling pathway in hepatocellular carcinoma and its tumor microenvironment[J]. Journal of Clinical Hepatology, 2024, 40(4): 822-827. doi: 10.12449/JCH240429
[4]	Pinsheng HAN, Long YANG, Tao CUI, Yamin ZHANG. Role of tumor-associated macrophages in cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2023, 39(2): 469-473. doi: 10.3969/j.issn.1001-5256.2023.02.035
[5]	Peng WANG, Jiannan QIU, Zhongxia WANG, Junhua WU, Chunping JIANG. Research advances in tumor-associated macrophages in hepatocellular carcinoma microenvironment[J]. Journal of Clinical Hepatology, 2023, 39(5): 1212-1218. doi: 10.3969/j.issn.1001-5256.2023.05.033
[6]	Yanxin TIAN, Na LI, Lei GAO, Jia WU, Ying ZHU. Influence of the interaction between tumor microenvironment and liver cancer stem cells on the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(3): 684-692. doi: 10.3969/j.issn.1001-5256.2023.03.032
[7]	Chaoran YANG, Sirou LI, Yuan LIU, Zhiyuan HOU, Yuan WANG, Jihong YANG. Role of non-coding RNA on immune cells in tumor microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 961-967. doi: 10.3969/j.issn.1001-5256.2023.04.033
[8]	Yiyi ZHANG, Min XU. Research advances in the mechanism of tumor microenvironment in pancreatic cancer and related targeted therapy[J]. Journal of Clinical Hepatology, 2022, 38(4): 965-968. doi: 10.3969/j.issn.1001-5256.2022.04.046
[9]	Shun CHEN, Jun WANG. Advances in tumor microenvironment and immunotherapy of Cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(10): 2428-2432. doi: 10.3969/j.issn.1001-5256.2022.10.044
[10]	Wenhua YOU, Yuan LIANG, Ling LYU. Pathogenesis and clinical translation of intrahepatic cholangiocarcinoma in the era of precision medicine[J]. Journal of Clinical Hepatology, 2021, 37(4): 935-938. doi: 10.3969/j.issn.1001-5256.2021.04.045
[11]	Xiao HU, Dewen MAO, Chengyu YA. Association between cancer-associated fibroblasts and liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(2): 444-447. doi: 10.3969/j.issn.1001-5256.2021.02.041
[12]	Xueyan LI, Changjun WANG. Influence of hepatocellular carcinoma microenvironment on myeloid-derived suppressor cells[J]. Journal of Clinical Hepatology, 2021, 37(6): 1473-1476. doi: 10.3969/j.issn.1001-5256.2021.06.053
[13]	Feiyu ZHANG, Yakepu ADILA, Jinming ZHAO, Yanhang GAO. New advances in the treatment of pancreatic cancer by targeting tumor microenvironment[J]. Journal of Clinical Hepatology, 2021, 37(9): 2246-2248. doi: 10.3969/j.issn.1001-5256.2021.09.049
[14]	Zhang Yu, Jiang JianXin. Biological role of hypoxic microenvironment in pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(3): 708-712. doi: 10.3969/j.issn.1001-5256.2020.03.054
[15]	Liu Peng, Liu Kui, Pei JinYu, Wang YiXiu, Cao GuangHua, Li LiYuan, Cao JingYu. Intrahepatic cholangiocarcinoma with paraneoplastic syndrome of hyperprolactinemia:A case report[J]. Journal of Clinical Hepatology, 2020, 36(8): 1822-1823. doi: 10.3969/j.issn.1001-5256.2020.08.029
[16]	Hu Lei, Gao Li, Chen AiDong. Regulatory effect of tumor-associated neutrophils in the development and progression of liver cancer[J]. Journal of Clinical Hepatology, 2020, 36(9): 2100-2102. doi: 10.3969/j.issn.1001-5256.2020.09.043
[17]	Liu Jian, Gao ChiDan, Zhang LiXin, Quan Gang, Zhang YuShun, Li JingDong. Influence of neutrophil-lymphocyte ratio on prognosis of liver cancer:a meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(7): 1305-1309. doi: 10.3969/j.issn.1001-5256.2017.07.020
[18]	Zhang TingTing, Zhao XiangQian, Liu Zhe, Jiao ShunChang, Bai Li. Preoperative neutrophil-lymphocyte ratio is an independent prognostic factor for hepatocellular carcinoma after radical resection[J]. Journal of Clinical Hepatology, 2015, 31(6): 927-931. doi: 10.3969/j.issn.1001-5256.2015.06.024
[19]	Ma DeNing, Zhu XiaoDong, Tang ZhaoYou. Role of cancer- associated fibroblasts in growth and metastasis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(9): 865-868. doi: 10.3969/j.issn.1001-5256.2014.09.007

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2)

Get Citation

PDF

XML

Article Metrics

Article views (48) PDF downloads(7)

Components of tumor stroma-immune microenvironment and their interactions in intrahepatic cholangiocarcinoma

DOI: 10.12449/JCH250331

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Components of tumor stroma-immune microenvironment and their interactions in intrahepatic cholangiocarcinoma

DOI: 10.12449/JCH250331

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content